Summary
Merck & Co., Inc. (MRK) filed an 8-K on July 24, 2009, primarily to disclose details regarding a settlement of class action lawsuits related to its proposed merger with Schering-Plough Corporation. The settlement, agreed upon by Schering-Plough, aims to resolve claims that the Schering-Plough board breached fiduciary duties in connection with the merger announcement, particularly concerning the timing relative to the publication of Phase II trial results for Schering-Plough's drug TRA. While Merck is indirectly involved as the merger partner, the core of the litigation and settlement pertains to Schering-Plough's disclosures and board actions. The filing provides additional information on financial advisor fees, arbitration regarding specific drugs, and a timeline of public disclosures for the TRA-PCI trial. Investors should note that both companies deny the allegations in the consolidated complaint.
Key Highlights
- 1Settlement reached in class action lawsuits challenging the proposed merger between Merck and Schering-Plough, initiated by Schering-Plough shareholders.
- 2The litigation primarily alleges breach of fiduciary duties by Schering-Plough's board regarding the merger announcement timing relative to clinical trial results publication.
- 3Additional disclosures provided regarding financial advisor fees for both Schering-Plough and Merck.
- 4Information on arbitration concerning Remicade and golimumab is also disclosed, with references to prior filings.
- 5Merck and Schering-Plough deny all allegations made in the consolidated amended complaint.
- 6The filing includes tables showing stock prices for both companies during the week of the merger announcement and a timeline of public disclosures for the TRA-PCI trial.
- 7Negotiations on the merger agreement included discussions and revisions to deal protection provisions, termination fees, and matching periods.